Topline results of phase 3 investigational study of VONVENDI™ meets primary endpoint
Shire announced topline results from a Phase 3 clinical trial of VONVENDITM [von Willebrand factor (Recombinant)] to treat bleeds in elective surgical settings for adults with severe von Willebrand disease, the most common inherited bleeding disorder. December 02, 2016